We have submitted an IND for the first in-human trial of SynKIR-110, a KIR-CAR T cell Immunotherapy. Thank you to our focused and committed team for bringing us closer to helping patients with unmet medical needs. Full release: prn.to/3QDgjRp  #celltherapy #VerismoTx

We are grateful to play a role in helping patients with a #RareDisease. Our #STAR101 trial testing our #SynKIR110 #KIRCAR will open in the 1st quarter of 2023 if approved by the #FDA.

Penn spinout company Verismo Therapeutics announced that it has submitted an Investigational New Drug application to the FDA requesting approval to initiate its first-in-human Phase 1 clinical trial of its KIR-CAR T-cell immunotherapy drug SynKIR-110. prnewswire.com/news-releases/…

We are excited to join Alliance for Regenerative Medicine (ARM). ARM and its members make help make meaningful changes in patients lives and we are honored to be a part of it. #cancer #regenerativemedicine #patientsfirst #synkir110

Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110. Following the FDA's clearance of its IND, the UPenn spinout will start studying its cell therapy in patients with mesothelin-expressing ovarian cancer,... ow.ly/cy8y1041VUH

#VerismoTherapeutics Announces #FDA Clearance of #IND Application for #SynKIR110 a #KIRCAR #TCell #Immunotherapy Candidate 1stoncology.com/blog/verismo-t…

Congrats to Verismo Therapeutics on their FDA Clearance of their Investigational New Drug application for SynKIR-110™, a KIR-CAR T cell immunotherapy candidate. pipelinereview.com/index.php/2022…

A Penn #spinout Verismo Therapeutics received FDA approval for a drug study of a KIR-CAR T Cell #Immunotherapy to treat diseases with low survival rates and an urgent need for successful treatment options. #techtransfer bit.ly/3rDmZV0

We have been nominated for Breakthrough Company of the Year at the 3rd Annual BioBuzz Awards! Cast your vote for us today! The deadline is 12/2 and for each vote a donation of $0.25 for STEM programming in South Baltimore communities. #Cancer #STEM tinyurl.com/29jp5ny7

Verismo Therapeutics Expands Quality and Compliance Team: buff.ly/3WME24G #CARTCR #immunotherapy

Happy #CholangiocarcinomaAwarenessDay! We’re proud to join the fight against bile duct cancer and support those affected by this devastating disease. #Cholangiocarcinoma #CancerAwareness #FightCancer #SynKIR110 #WorldCCADay #PledgeforCCA

Tomorrow is Rare Disease Day! We at Verismo honor the millions of individuals & families affected by rare diseases & are committed to developing treatments that provide relief & hope. #ShareYourColors #LightUpForRare #RareDiseaseDay

We're thrilled to announce that Verismo has secured $7M of pre-Series A financing to advance their KIR-CAR platform technology, designed to improve persistence and efficacy against aggressive solid tumors. #KIRCAR #VerismoTherapeutics Full release: tinyurl.com/kbkzn3p3

FDA grants Verismo Therapeutics Fast Track designation for SynKIR-110, a potential new treatment for pleural mesothelioma, a rare and aggressive cancer. We look forward to advancing SynKIR-110 in our Phase 1 trial to reach patients sooner. #CART #Mesothelioma #VerismoTherapeutics

Raymond Luke is the director of manufacturing science and technology and head of chemistry, manufacturing and controls at Verismo Therapeutics. Get to know more about the 40 Under Forty honoree. bizjournals.com/philadelphia/n…

📰 #NEWS: Verismo Therapeutics and the Center for Vaccine and Cell Production Facility at the University of Pennsylvania Expand Partnership aprpub.com/Verismo-Therap… Verismo Therapeutics Penn Medicine #Partnership #CVPF #ClinicalCellManufacturing